There is less than a 10% chance that next February there will not be at least one vaccine that is safe enough in the short term.

Miguel Ángel Temprano participate this time in the Open Market program directed by Marta Isern more in his capacity as Biochemist than as a fund manager to give his opinion on the incident caused by the interruption of the AstraZeneca clinical study on the Covid 19 vaccine and to analyze the evolution of the scientific studies that are being carried out in the race for the Vaccine.